US to spend $10 million to curb bird flu in farm workers, including seasonal flu vaccine push
By Leah Douglas and Julie Steenhuysen
July 30 (Reuters) -The U.S. Centers for Disease Control and Prevention said on Tuesday it plans to spend $10 million to curb farm worker bird flu infections, including $5 million for seasonal flu vaccines, as part of its efforts to avoid further spread and mutation of the virus.
The ongoing outbreak of bird flu has infected poultry flocks in nearly every state since 2022 and more than 170 dairy herds in 13 states since March, according to the U.S. Department of Agriculture.
Thirteen poultry and dairy farm workers have contracted the virus in Colorado, Michigan, and Texas, according to the CDC. Nine of those cases were detected in July among workers killing chickens at two poultry farms with bird flu in Colorado.
The risk to the general public from bird flu is still low, said CDC's principal director Nirav Shah on a call with reporters.
The agency will allocate $5 million to organizations including the National Center for Farmworker Health to educate and train workers on protecting themselves from bird flu, and another $5 million to providing seasonal flu shots to farm workers, Shah said.
The vaccine push could reduce the risk that workers become co-infected with the seasonal flu and bird flu at the same time, which could lead to flu virus mutations, Shah said.
"Preventing seasonal influenza for these workers, many of whom are also exposed to bird flu, may reduce risks of new strains of influenza emerging," he said.
The agency is hoping to vaccinate all of the nation's approximately 200,000 livestock workers, Shah said.
Reporting by Leah Douglas in Washington and Julie Steenhuysen in Chicago; additional reporting by Ahmed Aboulenein in Washington; Editing by Bill Berkrot
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
